Europese Unie - Nederlands - EMA (European Medicines Agency)

theramex ireland limited - teriparatide - osteoporose - calcium homeostase - livogiva is indicated in adults. behandeling van osteoporose bij postmenopauzale vrouwen en bij mannen met een verhoogd risico op fracturen. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. de behandeling van osteoporose in verband met de aanhoudende systemische glucocorticoïden therapie bij vrouwen en mannen met een verhoogd risico op fracturen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatide - osteoporose - calcium homeostase - sondelbay is indicated in adults. behandeling van osteoporose bij postmenopauzale vrouwen en bij mannen met een verhoogd risico op fracturen. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. de behandeling van osteoporose in verband met de aanhoudende systemische glucocorticoïden therapie bij vrouwen en mannen met een verhoogd risico op fracturen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostase - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Europese Unie - Nederlands - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostase - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Europese Unie - Nederlands - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplasmata van de borst - antineoplastische middelen - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

theramex ireland limited - abaloparatide - osteoporosis, postmenopausal; osteoporosis - calcium homeostase - behandeling van osteoporose bij postmenopauzale vrouwen met een verhoogd risico op fracturen.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

cheplapharm arzneimittel gmbh ziegelhof 24 17489 greifswald (duitsland) - calciumcarbonaat (e 170) 1250 mg/stuk samenstelling overeenkomend met ; calcium (ca2+) 500 mg/stuk ; cholecalciferol concentraat, poedervorm 8 mg/stuk samenstelling overeenkomend met ; cholecalciferol 20 µg/stuk ; samenstelling overeenkomend met cholecalciferol 800 ie/stuk - kauwtablet - isomalt (e 953) ; magnesiumstearaat (e 470b) ; maÏszetmeel, gemodificeerd (modificatie onbekend ; mono- en diglyceriden van vetzuren (e 471) ; natriumascorbaat (e 301) ; povidon k 30 (e 1201) ; saccharose ; siliciumdioxide (e 551) ; sinaasappelsmaakstof 052595a firmenich ; sucralose (e 955) ; tocoferol, dl-alfa (e 307) ; triglyceriden middellange keten ; xylitol (e 967), isomalt (e 953) ; magnesiumstearaat (e 470b) ; maÏszetmeel, gemodificeerd (modificatie onbekend, (e 1450) ; mono- en diglyceriden van vetzuren (e 471) ; natriumascorbaat (e 301) ; povidon k 30 (e 1201) ; saccharose ; siliciumdioxide (e 551) ; sinaasappelsmaakstof 052595a firmenich ; sucralose (e 955) ; tocoferol, dl-alfa (e 307) ; triglyceriden middellange keten ; xylitol (e 967), - calcium, combinations with vitamin d and/or other drugs

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

orifarm generics a.s. - calciumcarbonaat 1250 mg - eq. calcium 500 mg; cholecalciferol 800 ie - kauwtablet - 500 mg - 800 iu - calciumcarbonaat 1250 mg; cholecalciferol 800 ie - calcium, combinations with vitamin d and/or other drugs

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

orifarm generics a.s. - calciumcarbonaat 1250 mg - eq. calcium 500 mg; cholecalciferol 800 ie - kauwtablet - calcium, combinations with vitamin d and/or other drugs

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

b. braun melsungen ag (melsungen) carl-braun-strasse 1 34212 melsungen (duitsland) - natriumwaterstofcarbonaat (e 500 (ii)) - oplossing voor infusie - dinatriumedetaat 2-water ; water, gezuiverd, - electrolytes